Program Goals Introduction Case 1: A 44-Year-Old Woman.

Slides:

Advertisements

Similar presentations

Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib.

Advertisements

이근욱 분당서울대학교병원/서울의대 혈액종양내과 부교수

Stage III and IV Malignant Melanoma Jennifer Carter 09/12/17.

CCO Independent Conference Highlights

Bladder Cancer: A New Era in Treatment

CCO Independent Conference Coverage

COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Nat. Rev. Clin. Oncol. doi: /nrclinonc

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Treatment Algorithms in Melanoma: Past, Present, and Future

The Immune System. The Immune System Adaptive Immune Response.

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Discussion Outline Cells of the Immune System.

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Introduction to Checkpoint Inhibitors

Spotlight on Immuno-Oncology in Melanoma

Metastatic Renal Cell Carcinoma

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Activity Goals. Activity Goals Discussion Topics.

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Basics of Immunotherapy Potential Therapeutic Targets.

Managing gBRCA-Positive Metastatic Breast Cancer

Treating mRCC After Initial Antiangiogenic Therapy:

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Braf-MUTATION POSITIVE melanoma: a case conference

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Activity Goals. Activity Goals Program Overview.

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Advances in Gastrointestinal Cancers

Patient-Centered Management in BRAF-Positive Metastatic Melanoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Targeting T Cell Co-receptors for Cancer Therapy

The Changing Field of Melanoma: Ipilimumab.

Preparing for Checkpoint Inhibitors in Breast Cancer

Adjuvant Therapy in Melanoma

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Going Beyond EXTREME in Head and Neck Cancer

Moving Care Forward in Advanced Gastric Cancer

New Options for the Treatment of Hepatocellular Carcinoma

Immune Checkpoint Inhibitors in Lung Cancer

The Nurse View.

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Recent Developments in the Treatment of Advanced and Metastatic RCC

Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.

Presentation transcript:

Program Goals

Introduction

Case 1: A 44-Year-Old Woman

Definition of High-Risk Melanoma

Trials of High-Dose Interferon-Alfa

Toxicity Profile of Interferon-Alfa

Ipilimumab: EORTC 18071 Study Design

Ipilimumab: EORTC 18071 Efficacy Data

Ipilimumab: EORTC 18071 Safety Data

US Intergroup E1609 Study Design

Phase 3 Adjuvant Therapy Trials

Case 1: Conclusion

Neoadjuvant Therapy Trials

Case 2: A 54-Year-Old Man

Case 2: Treatment Options

Ipilimumab in Metastatic Melanoma

KEYNOTE-006: Study Design and Data

CheckMate 037 Trial of Nivolumab

CheckMate 067 and 069 Trials

Combined BRAF and MEK Inhibitors

Pembrolizumab in BRAF+ Melanoma

ECOG-ACRIN EA16134 Study Design

Conclusions on Anti-PD1 Antibodies

Brain Metastases in Melanoma

BREAK-MB: Phase 2 Trial of Dabrafenib

Case 3: A 65-Year-Old Man

Case 3: Managing the Patient's Colitis

Case 3: Steroid Taper

Managing Immune-Related AEs

Immunotherapy-Related Endocrinopathy

Management of Endocrinopathies

Common AEs With PD1 Inhibitors

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)